<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01893372</url>
  </required_header>
  <id_info>
    <org_study_id>2013-0225</org_study_id>
    <secondary_id>NCI-2013-02252</secondary_id>
    <nct_id>NCT01893372</nct_id>
  </id_info>
  <brief_title>Eltrombopag With or Without Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)</brief_title>
  <official_title>Phase II Study of Eltrombopag With or Without Continuation of Hypomethylating Agent After Hypomethylating Agent Failure For Patients With Myelodysplastic Syndrome (MDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The goal of this clinical research study is to learn if eltrombopag can help to control MDS.
      The safety of this drug will also be studied.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Groups:

      If you are found to be eligible to take part in this study, you will be assigned to 1 of 2
      arms.The selection of treatment arm will be made by you and your treating physician.

        -  If you are in Arm A, you will receive eltrombopag alone.

        -  If you are in Arm B, you will receive eltrombopag and will continue to receive the
           hypomethylating agent that you were receiving before you took part in this study.

      Study Drug Administration:

      You will take eltrombopag by mouth every day of each 28-day study cycle. If you are in Arm B,
      you will also continue to take the hypomethylating agent you took before joining the study at
      the same dosing schedule you were receiving before entering this study.

      Eltrombopag should be taken on an empty stomach (1 hour before or 2 hours after a meal). Do
      not eat calcium-rich foods (such as dairy products and calcium fortified juices), or take
      other drugs (such as antacids) or supplements containing iron, calcium, aluminum, magnesium,
      selenium, and/or zinc for 2 hours before or 4 hours after taking eltrombopag. If a dose of
      eltrombopag is vomited, it should not be made up or re-taken on the same day. If the morning
      dose is missed, it may be taken up until 5:00 PM on the same day.

      Study Visits:

      On Day 1 of all Cycles:

        -  You will have a physical exam including vital signs.

        -  Blood (about 2-3 teaspoons) will be drawn for routine tests.

      On Days 8, 15, and 22 of Cycle 1:

        -  Your vital signs (blood pressure, heart rate, and temperature) will be measured.

        -  Blood (about 2-3 teaspoons) will be drawn for routine tests.

      If the doctor thinks it is needed, on Day 1 of every 3 cycles (Cycles 3, 6, 9, and so on),
      you will also have a bone marrow aspirate/biopsy to check the status of the disease and for
      cytogenetic testing.

      Length of Study:

      You may continue taking the study drug(s) for as long as the doctor thinks it is in your best
      interest. You will no longer be able to take the study drug(s) if the disease gets worse, if
      intolerable side effects occur, or if you are unable to follow study directions.

      Your participation on the study will be over after the follow-up visits.

      End-of-Treatment Visit:

      Within 5 days of your last dose of study drug, you will come to the clinic for an
      end-of-treatment visit. The following procedures will be performed:

        -  You will have a physical exam.

        -  Blood (about 2-3 teaspoons) will be drawn for routine tests.

        -  You may have a bone marrow aspirate/biopsy collected to check the status of the disease
           and for cytogenetic testing.

      Follow-up Visit:

      About 28 days after your last dose of study drug, you will come to the clinic for a follow-up
      visit. the following procedures will be performed:

        -  You will have a physical exam.

        -  Blood (about 2-3 teaspoons) will be drawn for routine tests.

      This is an investigational study. Eltrombopag is FDA approved and commercially available for
      the treatment of low platelet counts in patients with idiopathic thrombocytopenic purpura
      (ITP -- a severe bleeding disease). Its use in this study is investigational. Azacitidine and
      decitabine are each FDA approved for the treatment of MDS and are commercially available. The
      study doctor can explain how the study drug(s) are designed to work.

      Up to 46 patients will take part in this study. All will be enrolled at MD Anderson.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2013</start_date>
  <completion_date type="Actual">January 6, 2019</completion_date>
  <primary_completion_date type="Actual">January 6, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>After second 28 day cycle</time_frame>
    <description>Overall response rate (ORR) based on the International Working Group (IWG)-2006 criteria, which include complete remission (CR), partial remission (PR), and major hematologic improvement (HI). Patients' overall response assessed after at least 2 cycles of treatment and no more than after 6 cycles of treatment and each cycle is 28 days. CR is Bone marrow of &lt;/= 5% myeloblasts with normal maturation of cell lines, persistent dysplasia and a hemoglobin &gt;/= 11g/dl, platelets &gt;/= 100x10^9/L, neutrophils &gt;/= 1.0x10^9/L and 0% blasts. PR is the same as CR but bone marrow blasts decreased by &gt;/=50% but still 5% over pre-treatment. HI is described by the number of individually affected cell lines. (E = Erythroid, N = Neutrophils, P = Platelet). HI-E is a 2 gram increase in hemoglobin. HI-N is at least a 100% increase or an absolute increase of more than 500/mm^3. HI-P is an absolute increase of 30/mm^3 or a 50% increase</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Through study completion. Up to 3 years, 3 months.</time_frame>
    <description>Overall Survival (OS) was measured from the time of study enrollment until death from any cause or fate of the last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Transforming From Myelodysplastic Syndrome (MDS) to Acute Myeloid Leukemia (AML)</measure>
    <time_frame>Up to 3 years, 3 months.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Achieving a Platelet Response</measure>
    <time_frame>3 Years</time_frame>
    <description>Platelet response is Hematologic Improvement with platelet response (HI-P), defined as an absolute increase of &gt;/= 30 x 10^9/L for patients starting with &gt;20 x 10^9/L platelets or increase from &lt;20 x 10^9/L to &gt;20 x 10^9/L and by at least 100%</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Leukemia</condition>
  <arm_group>
    <arm_group_label>Eltrombopag</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eltrombopag 200 mg by mouth daily in a 28 day cycle.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eltrombopag + Hypomethylating Agent (HMA)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.
The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eltrombopag</intervention_name>
    <description>200 mg by mouth daily in a 28 day cycle.</description>
    <arm_group_label>Eltrombopag</arm_group_label>
    <arm_group_label>Eltrombopag + Hypomethylating Agent (HMA)</arm_group_label>
    <other_name>Promacta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hypomethylating Agent (HMA)</intervention_name>
    <description>The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.</description>
    <arm_group_label>Eltrombopag + Hypomethylating Agent (HMA)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed, informed consent must be obtained prior to any study specific procedures.

          2. Subjects with a histologically confirmed diagnosis of MDS by FAB criteria, including
             both MDS and RAEB-T (AML with 20-30% blasts and multilineage dysplasia) by World
             Health Organization (WHO) classification are eligible.

          3. Patients must have completed at least 4 cycles of hypomethylating agent therapy (e.g
             azacitidine or decitabine) with failure to achieve at least a partial response, or
             with the presence of ongoing cytopenias per International Working Group (IWG)
             (platelet count &lt; 100x10^9/L, hemoglobin &lt;11g/L or Absolute Neutrophil Count (ANC)
             &lt;1x10^9/L). Patients with progressive disease on HMA-therapy prior to this time point
             are also eligible at the time of documented progression. Therapy with decitabine
             analogs (i.e. SGI-110) will be considered as decitabine for the purposes of this
             study.

          4. Platelet count &lt;100x10^9/L

          5. Low, intermediate-1, intermediate-2 or High-risk category by International Prognostic
             Scoring System (IPSS)

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

          7. Adequate liver function, as evidenced by a serum bilirubin &lt;/=2x the ULN (except for
             patients with a confirmed diagnosis of Gilbert's Disease) and an Alanine
             Aminotransferase (ALT) or Aspartate Aminotransferase (AST) &lt;/=3x the laboratory Upper
             Limit of Normal (ULN).

          8. Serum creatinine &lt;/=2x upper limit of normal

          9. Subjects must be&gt;/= 18 years of age at the time of informed consent, because no dosing
             or adverse event data are currently available on the use of eltrombopag in children.

         10. Subject is practicing an acceptable method of contraception (documented in chart).
             Female subjects (or female partners of male subject) must either be of
             non-childbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal
             ligation or post-menopausal &gt; 1 year), or of childbearing potential and use one of the
             following highly effective methods of contraception (i.e. Pearl index &lt; 1.0%) from 2
             weeks prior to administration of study medication, throughout the study, and 28 days
             after completion or premature discontinuation from the study: - Complete abstinence
             from intercourse; - Intrauterine device (IUD); - Two forms of barrier contraception
             (diaphragm plus spermicide, and for males condom plus spermicide); - Male partner is
             sterile prior to entry into the study and is the only partner of the female; -
             Systemic contraceptives (combined or progesterone only).

         11. Patients must have recovered from acute toxicity (to grade 1 or less) of all previous
             therapy prior to enrollment. Treatment may start earlier if necessitated by the
             patient's medical condition (e.g. progressive disease) following discussion with the
             Investigator.

        Exclusion Criteria:

          1. Subjects with any prior exposure to a thrombopoietin-receptor agonist

          2. Any prior or co-existing medical condition that in the investigator's judgment will
             substantially increase the risk associated with the subject's participation in the
             study

          3. Psychiatric disorders or altered mental status precluding understanding of the
             informed consent process and/or completion of the necessary study procedures

          4. Active uncontrolled serious infection or sepsis at study enrollment

          5. Clinically significant gastrointestinal disorders that may interfere with absorption
             of drug.

          6. History of arterial thrombosis (i.e. stroke) in the past year

          7. History of venous thrombosis currently requiring anti-coagulation therapy

          8. Unstable angina, congestive heart failure (New York Heart Association (NYHA) &gt; Class
             II), uncontrolled hypertension (diastolic blood pressure &gt; 100mmHg), or recent (within
             1 year) myocardial infarction

          9. Subjects with a QTc &gt; 480 msec (QTc &gt; 510 msec for subjects with Bundle Branch Block)
             at baseline

         10. Pregnant or breast-feeding because there are no adequate and well-controlled studies
             of eltrombopag use in pregnancy and it is unknown whether eltrombopag is excreted in
             human milk.

         11. Subjects with known history of human immunodeficiency virus (HIV) or active infection
             with hepatitis C virus (HCV) or hepatitis B virus (HBV), because eltrombopag is
             hepatically cleared, and underlying hepatic impairment may lead to an increased risk
             of hepatotoxicity. Eltrombopag has not been evaluated with combination antiretroviral
             regimens.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Courtney DiNardo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>University of Texas MD Anderson Cancer Center Website</description>
  </link>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>July 2, 2013</study_first_submitted>
  <study_first_submitted_qc>July 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 9, 2013</study_first_posted>
  <results_first_submitted>January 23, 2020</results_first_submitted>
  <results_first_submitted_qc>February 5, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">February 18, 2020</results_first_posted>
  <last_update_submitted>February 5, 2020</last_update_submitted>
  <last_update_submitted_qc>February 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Leukemia</keyword>
  <keyword>Myelodysplastic syndrome</keyword>
  <keyword>MDS</keyword>
  <keyword>Overall response rate</keyword>
  <keyword>ORR</keyword>
  <keyword>Eltrombopag</keyword>
  <keyword>Promacta</keyword>
  <keyword>Hypomethylating Agent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 23, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/72/NCT01893372/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Details: October 2013 to January 2016</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Eltrombopag</title>
          <description>Eltrombopag 200 mg by mouth daily in a 28 day cycle.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.</description>
        </group>
        <group group_id="P2">
          <title>Eltrombopag + Hypomethylating Agent (HMA)</title>
          <description>Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.
The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.
Hypomethylating Agent (HMA): The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eltrombopag</title>
          <description>Eltrombopag 200 mg by mouth daily in a 28 day cycle.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.</description>
        </group>
        <group group_id="B2">
          <title>Eltrombopag + Hypomethylating Agent (HMA)</title>
          <description>Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.
The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.
Hypomethylating Agent (HMA): The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="22"/>
            <count group_id="B3" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74" lower_limit="61" upper_limit="80"/>
                    <measurement group_id="B2" value="72" lower_limit="42" upper_limit="84"/>
                    <measurement group_id="B3" value="72" lower_limit="42" upper_limit="84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="22"/>
                    <measurement group_id="B3" value="229"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Response Rate (ORR)</title>
        <description>Overall response rate (ORR) based on the International Working Group (IWG)-2006 criteria, which include complete remission (CR), partial remission (PR), and major hematologic improvement (HI). Patients' overall response assessed after at least 2 cycles of treatment and no more than after 6 cycles of treatment and each cycle is 28 days. CR is Bone marrow of &lt;/= 5% myeloblasts with normal maturation of cell lines, persistent dysplasia and a hemoglobin &gt;/= 11g/dl, platelets &gt;/= 100x10^9/L, neutrophils &gt;/= 1.0x10^9/L and 0% blasts. PR is the same as CR but bone marrow blasts decreased by &gt;/=50% but still 5% over pre-treatment. HI is described by the number of individually affected cell lines. (E = Erythroid, N = Neutrophils, P = Platelet). HI-E is a 2 gram increase in hemoglobin. HI-N is at least a 100% increase or an absolute increase of more than 500/mm^3. HI-P is an absolute increase of 30/mm^3 or a 50% increase</description>
        <time_frame>After second 28 day cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag</title>
            <description>Eltrombopag 200 mg by mouth daily in a 28 day cycle.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag + Hypomethylating Agent (HMA)</title>
            <description>Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.
The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.
Hypomethylating Agent (HMA): The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Response Rate (ORR)</title>
          <description>Overall response rate (ORR) based on the International Working Group (IWG)-2006 criteria, which include complete remission (CR), partial remission (PR), and major hematologic improvement (HI). Patients' overall response assessed after at least 2 cycles of treatment and no more than after 6 cycles of treatment and each cycle is 28 days. CR is Bone marrow of &lt;/= 5% myeloblasts with normal maturation of cell lines, persistent dysplasia and a hemoglobin &gt;/= 11g/dl, platelets &gt;/= 100x10^9/L, neutrophils &gt;/= 1.0x10^9/L and 0% blasts. PR is the same as CR but bone marrow blasts decreased by &gt;/=50% but still 5% over pre-treatment. HI is described by the number of individually affected cell lines. (E = Erythroid, N = Neutrophils, P = Platelet). HI-E is a 2 gram increase in hemoglobin. HI-N is at least a 100% increase or an absolute increase of more than 500/mm^3. HI-P is an absolute increase of 30/mm^3 or a 50% increase</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Survival (OS)</title>
        <description>Overall Survival (OS) was measured from the time of study enrollment until death from any cause or fate of the last follow-up.</description>
        <time_frame>Through study completion. Up to 3 years, 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag</title>
            <description>Eltrombopag 200 mg by mouth daily in a 28 day cycle.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag + Hypomethylating Agent (HMA)</title>
            <description>Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.
The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.
Hypomethylating Agent (HMA): The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival (OS)</title>
          <description>Overall Survival (OS) was measured from the time of study enrollment until death from any cause or fate of the last follow-up.</description>
          <units>Weeks</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.9" lower_limit="4.8" upper_limit="165.1"/>
                    <measurement group_id="O2" value="40.4" lower_limit="2.3" upper_limit="150.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Transforming From Myelodysplastic Syndrome (MDS) to Acute Myeloid Leukemia (AML)</title>
        <time_frame>Up to 3 years, 3 months.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag</title>
            <description>Eltrombopag 200 mg by mouth daily in a 28 day cycle.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag + Hypomethylating Agent (HMA)</title>
            <description>Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.
The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.
Hypomethylating Agent (HMA): The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Transforming From Myelodysplastic Syndrome (MDS) to Acute Myeloid Leukemia (AML)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Achieving a Platelet Response</title>
        <description>Platelet response is Hematologic Improvement with platelet response (HI-P), defined as an absolute increase of &gt;/= 30 x 10^9/L for patients starting with &gt;20 x 10^9/L platelets or increase from &lt;20 x 10^9/L to &gt;20 x 10^9/L and by at least 100%</description>
        <time_frame>3 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eltrombopag</title>
            <description>Eltrombopag 200 mg by mouth daily in a 28 day cycle.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.</description>
          </group>
          <group group_id="O2">
            <title>Eltrombopag + Hypomethylating Agent (HMA)</title>
            <description>Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.
The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.
Hypomethylating Agent (HMA): The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Achieving a Platelet Response</title>
          <description>Platelet response is Hematologic Improvement with platelet response (HI-P), defined as an absolute increase of &gt;/= 30 x 10^9/L for patients starting with &gt;20 x 10^9/L platelets or increase from &lt;20 x 10^9/L to &gt;20 x 10^9/L and by at least 100%</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion. Up to 3 years, 3 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Eltrombopag</title>
          <description>Eltrombopag 200 mg by mouth daily in a 28 day cycle.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.</description>
        </group>
        <group group_id="E2">
          <title>Eltrombopag + Hypomethylating Agent (HMA)</title>
          <description>Eltrombopag in combination with continuation of hypomethylating agent in 28-day cycles. Eltrombopag 200 mg by mouth daily in a 28 day cycle.
The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study. Eltrombopag should be initiated at the start of the next HMA cycle whenever possible so the start date of both agents is consistent.
Eltrombopag: 200 mg by mouth daily in a 28 day cycle.
Hypomethylating Agent (HMA): The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Aenmia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillaiton</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Rectal Hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title vocab="CTCAE (3.0)">Abdominal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benigh, malignantand unspecified</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blurred Vision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Intermittent Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Flu Like Symptoms</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Intermittent Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bladder Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Joint Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Abcess Under Arm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Courtney DiNardo, MD/Associate Professor</name_or_title>
      <organization>The Universtiy of Texas MD Anderson Cancer Center</organization>
      <phone>713-794-1141</phone>
      <email>CDiNardo@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

